<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5583">
  <stage>Registered</stage>
  <submitdate>3/05/2011</submitdate>
  <approvaldate>3/05/2011</approvaldate>
  <nctid>NCT01348828</nctid>
  <trial_identification>
    <studytitle>Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System</studytitle>
    <scientifictitle>Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP-0003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Abdominal Aortic Aneurysm</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)

Treatment: devices: Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)
Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - Major adverse events defined as:
All-cause death
Bowel ischemia
Myocardial infarction
Paraplegia
Renal failure
Respiratory failure
Stroke
Blood loss &gt;=1,000cc</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Feasibility/effectiveness - Successful device delivery and deployment with patency of the renal and aortic endografts without Type I/III endoleak.</outcome>
      <timepoint>30 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural/in-hospital evaluations - Anesthesia time; fluoroscopy time; contrast volume; estimated blood loss; % requiring transfusion; procedure time; ICU time; time to hospital discharge</outcome>
      <timepoint>Procedurally and to hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality - All-cause and aneurysm-related</outcome>
      <timepoint>Procedurally and to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Events - All-cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, blood loss &gt;1,000cc</outcome>
      <timepoint>&gt;30 Days to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events - All serious and non-serious adverse events</outcome>
      <timepoint>Procedurally and to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Dysfunction - Reduction in estimated glomerular filtration rate (eGFR) &gt;30% from the preoperative value</outcome>
      <timepoint>30 Days, 6 Months and Years 1 to 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Aneurysm Rupture - Internal bleeding or leaking of blood from the aneurysm subsequent to the index procedure</outcome>
      <timepoint>Procedurally and to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Conversion to Open Repair - Open surgical repair of the aortic aneurysm due to unsuccessful delivery or deployment of the stent graft, due to complications or other clinical situations that precluded successful endovascular treatment, or at any time following initial successful endovascular treatment for any reason</outcome>
      <timepoint>Procedurally and to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distal Blood Flow - Ankle-brachial index measurements and changes over time</outcome>
      <timepoint>Pre-discharge, 30 Days, 6 Months, and Years 1 to 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Stent Graft Patency and Integrity - Patent luminal flow; absence of kinking, stenosis, occlusion, stent fracture, graft failure, or renal infarct &gt;30%</outcome>
      <timepoint>30 Days, 6 Months, and Years 1 to 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent Graft Patency and Integrity - Bifurcated and fenestrated stent graft patent luminal flow; absence of stent fracture or graft fatigue/failure</outcome>
      <timepoint>30 Days, 6 Months, and Years 1 to 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endograft Performance - Change in aneurysm sac diameter from the first post-procedural measurement; incidence of endoleak; incidence of device migration; incidence of limb occlusion</outcome>
      <timepoint>30 Days, 6 Months, and Years 1 to 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Procedures - Non-diagnostic intervention after the index procedure intended to correct or repair an endoleak (device-related: Type I (proximal or distal), Type III, Type IV; non-device related: Type II), device migration, or other device defect.</outcome>
      <timepoint>30 Days, 6 Months, and Years 1 to 5</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adequate iliac/femoral access compatible with the required delivery systems

          -  Non-aneurysmal infrarenal aortic neck &lt;15mm in length

          -  Most caudal renal artery to aortoiliac bifurcation length &gt;= 70

          -  SMA to aortoiliac bifurcation length &gt;=90mm

          -  Proximal non-aneurysmal aortic neck below the SMA with diameter 18 to 34 mm, length
             &gt;=15mm and angle &lt;=60° to the aneurysm sac

          -  Angle &lt;=60° (clock face) between the SMA and CA

          -  Renal arteries both at or below the SMA by &lt;=35mm and within 30mm of each other
             axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each
             other

          -  Common iliac artery distal fixation site with: distal fixation length &gt;=15mm, with
             diameter &gt;=10 mm and &lt;=23 mm and angle &lt;=90° to the aortic bifurcation

          -  Ability to preserve at least one hypogastric artery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Life expectancy &lt;2 years as judged by the investigator

          -  Psychiatric or other condition that may interfere with the study

          -  Participating in the enrollment or 30-day follow-up phase of another clinical study

          -  Known allergy to any device component

          -  Coagulopathy or uncontrolled bleeding disorder

          -  Contraindication to contrast media or anticoagulants

          -  Ruptured, leaking, or mycotic aneurysm

          -  Aortic dissection Serum creatinine (S-Cr) level &gt;2.0 mg/dL

          -  Traumatic vascular injury

          -  Active systemic or localized groin infection

          -  Connective tissue disease (e.g., Marfan's Syndrome)

          -  Recent(within prior three months)cerebrovascular accident

          -  Recent(within prior three months)myocardial infarction

          -  Prior renal transplant

          -  Length of either renal artery to be stented &lt;12mm

          -  Significant occlusive disease or calcification of either renal artery (&gt;70%)

          -  An essential accessory renal artery

          -  Indispensable inferior mesenteric artery

          -  Untreated aneurysmal disease of the descending thoracic aorta

          -  Clinically significant mural thrombus circumferentially in the suprarenal segment

          -  Prior iliac artery stent implanted that may interfere with delivery system
             introduction

          -  Unsuitable vascular anatomy

          -  Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Endologix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated
      Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01348828</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel Clair, MD</name>
      <address>The Cleveland Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>